Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to UK£18.25, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 15x in the Biotechs industry in Europe. Total loss to shareholders of 45% over the past three years. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to UK£18.75, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 45% over the past three years. Declared Dividend • Apr 01
First half dividend of UK£0.70 announced Dividend of UK£0.70 is the same as last year. Ex-date: 9th April 2026 Payment date: 24th April 2026 Dividend yield will be 9.1%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not covered by earnings (105% earnings payout ratio) nor is it covered by cash flows (101% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 17% to bring the payout ratio under control, which is more than the 1.5% EPS growth achieved over the last 5 years. Aankondiging • Mar 31
Bioventix PLC Confirms Interim Dividend for the Six Months Ended 31 December 2025, Payable on 24 April 2026 The Board of Bioventix PLC confirmed an interim dividend for the six months ended 31 December 2025 of 70 pence per share (2024: 70 pence per share). The shares will be marked ex-dividend on the 9 April 2026 and the dividend will be paid on 24 April 2026 to shareholders on the register at close of business on 10 April 2026. Reported Earnings • Mar 31
First half 2026 earnings released: EPS: UK£0.69 (vs UK£0.72 in 1H 2025) First half 2026 results: EPS: UK£0.69 (down from UK£0.72 in 1H 2025). Revenue: UK£6.16m (down 8.5% from 1H 2025). Net income: UK£3.63m (down 3.9% from 1H 2025). Profit margin: 59% (up from 56% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. New Risk • Mar 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£74.5m (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 103% Cash payout ratio: 112% Minor Risk Market cap is less than US$100m (UK£74.5m market cap, or US$98.5m). Aankondiging • Feb 25
BioVentix PLC Announces Appointment Of Chris Yates As Independent Non-Executive Director, Effective March 1, 2026 BioVentix PLC announced the appointment of Chris Yates as independent Non-Executive Director, effective March 1, 2026. Chris Yates brings extensive board-level and sector expertise, underpinned by over 20 years' experience operating within publicly listed company environments. Over the past decade, Chris has led the development and growth of Abingdon Health plc. Chris co-founded the business in 2008, initially serving as Non-Executive Director and then in 2015 becoming Chief Executive Officer until 2025 when he was appointed President of Abingdon Health USA and Group Chief Commercial Officer. Chris also serves as a Non-Executive Director and Chairman of the Audit Committee of AIM-listed Genedrive plc. Earlier in his career, Chris was CFO of AIM-listed companies Immunodiagnostic Systems Holdings PLC and Cozart plc. Chris is a Chartered Accountant and has a degree in economics from the University of Cambridge. Chris Yates, aged 51, holds current directorships and/or partnerships at Abingdon Analytical Limited, Compliance Solutions (Life Sciences) Limited, IVDeology Holdings Limited, IVDeology Limited, IVDeology UKRP Limited, Molecular Vision Limited, Genedrive plc, Foresite Diagnostics Limited, Find Out from Home Inc., and Abingdon Health USA Inc. Past directorships and/or partnerships (within the last five years) include Abingdon Health plc and Serascience Limited. New Risk • Dec 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 103% Cash payout ratio: 112% Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). Aankondiging • Nov 11
Bioventix PLC, Annual General Meeting, Dec 04, 2025 Bioventix PLC, Annual General Meeting, Dec 04, 2025. Location: farnham castle, farnham, surrey, gu9 0ag, United Kingdom Declared Dividend • Oct 29
Final dividend of UK£0.80 announced Shareholders will receive a dividend of UK£0.80. Ex-date: 6th November 2025 Payment date: 21st November 2025 Dividend yield will be 8.1%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not covered by earnings (103% earnings payout ratio) nor is it covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 15% to bring the payout ratio under control. However, EPS is expected to remain steady over the next year, which means the dividend may need to be reduced to reach a sustainable payout ratio. Reported Earnings • Oct 28
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: UK£1.45 (down from UK£1.55 in FY 2024). Revenue: UK£13.1m (down 3.6% from FY 2024). Net income: UK£7.58m (down 6.3% from FY 2024). Profit margin: 58% (down from 60% in FY 2024). Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 5.2%. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to UK£19.60, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 33% over the past three years. New Risk • Oct 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Aug 05
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to UK£24.50. The fair value is estimated to be UK£32.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has grown by 4.0%. Reported Earnings • Apr 04
First half 2025 earnings released: EPS: UK£0.72 (vs UK£0.77 in 1H 2024) First half 2025 results: EPS: UK£0.72 (down from UK£0.77 in 1H 2024). Revenue: UK£6.73m (flat on 1H 2024). Net income: UK£3.77m (down 6.2% from 1H 2024). Profit margin: 56% (down from 60% in 1H 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Declared Dividend • Apr 02
First half dividend increased to UK£0.70 Dividend of UK£0.70 is 2.9% higher than last year. Ex-date: 10th April 2025 Payment date: 25th April 2025 Dividend yield will be 6.5%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not covered by earnings (103% earnings payout ratio) nor is it covered by cash flows (108% cash payout ratio). The dividend has increased by an average of 21% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 15% to bring the payout ratio under control, which is more than the 3.4% EPS growth achieved over the last 5 years. Buy Or Sell Opportunity • Mar 31
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to UK£24.20. The fair value is estimated to be UK£31.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 8.6%. Revenue is forecast to decline by 0.8% in a year. Earnings are forecast to decline by 2.5% in the next year. Aankondiging • Mar 31
Bioventix PLC Announces Interim Dividend, Payable on April 25, 2025 The Board of Bioventix PLC announced an interim dividend of 70 pence per share which represents a 3% increase on the interim dividend paid last year (68 pence per share). The shares will be marked ex-dividend on the 10th April 2025 and the dividend will be paid on 25th April 2025 to shareholders on the register at close of business on 11th April 2025. Buy Or Sell Opportunity • Mar 06
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 27% to UK£27.40. The fair value is estimated to be UK£35.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 8.6%. Revenue is forecast to grow by 6.6% in a year. Earnings are forecast to grow by 9.9% in the next year. Aankondiging • Nov 09
Bioventix PLC, Annual General Meeting, Dec 05, 2024 Bioventix PLC, Annual General Meeting, Dec 05, 2024. Location: farnham castle, surrey, gu9 0ag, farnham United Kingdom Declared Dividend • Oct 30
Final dividend of UK£0.87 announced Shareholders will receive a dividend of UK£0.87. Ex-date: 7th November 2024 Payment date: 21st November 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (70% earnings payout ratio) but not adequately covered by cash flows (95% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to remain steady over the next year, which should provide adequate earnings cover for the dividend. Reported Earnings • Oct 29
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: UK£1.55 (down from UK£1.61 in FY 2023). Revenue: UK£13.6m (up 6.2% from FY 2023). Net income: UK£8.10m (down 3.3% from FY 2023). Profit margin: 60% (down from 65% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 7.1%. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Oct 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Declared Dividend • Mar 27
First half dividend increased to UK£0.68 Dividend of UK£0.68 is 9.7% higher than last year. Ex-date: 11th April 2024 Payment date: 26th April 2024 Dividend yield will be 3.5%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it adequately covered by cash flows (99% cash payout ratio). The dividend has increased by an average of 26% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. EPS is expected to grow by 5.1% over the next year, which should be enough to bring the dividend into a sustainable range. Reported Earnings • Mar 27
First half 2024 earnings released: EPS: UK£0.77 (vs UK£0.72 in 1H 2023) First half 2024 results: EPS: UK£0.77 (up from UK£0.72 in 1H 2023). Revenue: UK£6.68m (up 13% from 1H 2023). Net income: UK£4.02m (up 7.9% from 1H 2023). Profit margin: 60% (down from 63% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Feb 17
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 32% to UK£49.50. The fair value is estimated to be UK£40.60, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years. Earnings per share has grown by 7.6%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 12% in the next 2 years. Aankondiging • Nov 13
Bioventix PLC, Annual General Meeting, Dec 07, 2023 Bioventix PLC, Annual General Meeting, Dec 07, 2023, at 14:00 Coordinated Universal Time. Location: Farnham Castle, Farnham Surrey United Kingdom Upcoming Dividend • Nov 02
Upcoming dividend of UK£0.90 per share at 4.5% yield Eligible shareholders must have bought the stock before 09 November 2023. Payment date: 24 November 2023. Payout ratio is a comfortable 61% but the company is paying out more than the cash it is generating. Trailing yield: 4.5%. Lower than top quartile of British dividend payers (6.7%). Higher than average of industry peers (1.7%). Aankondiging • Oct 31
Bioventix PLC Announces Second Interim Dividend, Payable on 24 November 2023 Bioventix PLC announced a second interim dividend of 90 pence per share which, when added to the first interim dividend of 62 pence per share makes a total of 152 pence per share for the current year. Accordingly, a dividend of 90 pence per share will be paid in November 2023. The shares will be marked ex-dividend on 9 November 2023 and the dividend will be paid on 24 November 2023 to shareholders on the register at close of business on 10 November 2023. Reported Earnings • Oct 30
Full year 2023 earnings released: EPS: UK£1.61 (vs UK£1.47 in FY 2022) Full year 2023 results: EPS: UK£1.61 (up from UK£1.47 in FY 2022). Revenue: UK£12.8m (up 9.4% from FY 2022). Net income: UK£8.37m (up 9.1% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Oct 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Aankondiging • May 31
Bioventix plc Appoints Joanne (Jo) Pisani to the Board as an Independent Non-Executive Director Bioventix plc announced that it has appointed Joanne (Jo) Pisani to the Board, as an independent Non-Executive Director, with immediate effect. Jo will chair the Company's Audit Committee. Jo is a chartered engineer with a distinguished background in the Pharmaceutical, Life Sciences and Biotech sectors. She has held roles at GSK and BP in strategy, commercial and operational functions before working in strategic consultancy. She led PwC's UK Pharmaceutical and Life Sciences practice, assisting clients with developing strategy, designing and implementing transformational change and completing M&A transactions. Recent Insider Transactions • Apr 03
Independent Non-Executive Chairman recently sold UK£97k worth of stock On the 31st of March, Ian Nicholson sold around 3k shares on-market at roughly UK£39.00 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth UK£2.2m. This was Ian's only on-market trade for the last 12 months. Upcoming Dividend • Mar 30
Upcoming dividend of UK£0.62 per share at 3.9% yield Eligible shareholders must have bought the stock before 06 April 2023. Payment date: 21 April 2023. Payout ratio and cash payout ratio are on the higher end at 84% and 99% respectively. Trailing yield: 3.9%. Lower than top quartile of British dividend payers (6.0%). Higher than average of industry peers (2.5%). Reported Earnings • Mar 28
First half 2023 earnings released: EPS: UK£0.72 (vs UK£0.57 in 1H 2022) First half 2023 results: EPS: UK£0.72 (up from UK£0.57 in 1H 2022). Revenue: UK£5.90m (up 25% from 1H 2022). Net income: UK£3.73m (up 25% from 1H 2022). Profit margin: 63% (in line with 1H 2022). Revenue is forecast to grow 5.6% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 2% per year. Recent Insider Transactions • Feb 03
CEO & Director recently sold UK£2.2m worth of stock On the 31st of January, Peter Harrison sold around 58k shares on-market at roughly UK£37.50 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months. Price Target Changed • Nov 16
Price target increased to UK£43.00 Up from UK£37.00, the current price target is provided by 1 analyst. New target price is 19% above last closing price of UK£36.25. The company is forecast to post earnings per share of UK£1.49 for next year compared to UK£1.47 last year. Upcoming Dividend • Oct 27
Upcoming dividend of UK£1.00 per share Eligible shareholders must have bought the stock before 03 November 2022. Payment date: 18 November 2022. Payout ratio is on the higher end at 86%, and the cash payout ratio is above 100%. Trailing yield: 4.5%. Lower than top quartile of British dividend payers (6.1%). Higher than average of industry peers (2.2%). Reported Earnings • Oct 24
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: UK£1.47 (up from UK£1.29 in FY 2021). Revenue: UK£11.7m (up 7.2% from FY 2021). Net income: UK£7.67m (up 14% from FY 2021). Profit margin: 66% (up from 62% in FY 2021). The increase in margin was primarily driven by higher revenue. Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 2% per year. Price Target Changed • Apr 27
Price target increased to UK£43.00 Up from UK£37.00, the current price target is provided by 1 analyst. New target price is 25% above last closing price of UK£34.50. Stock is down 13% over the past year. The company is forecast to post earnings per share of UK£1.25 for next year compared to UK£1.29 last year. Upcoming Dividend • Mar 31
Upcoming dividend of UK£0.52 per share Eligible shareholders must have bought the stock before 07 April 2022. Payment date: 22 April 2022. Payout ratio is on the higher end at 83%, and the cash payout ratio is above 100%. Trailing yield: 4.3%. Lower than top quartile of British dividend payers (4.7%). Higher than average of industry peers (1.4%). Reported Earnings • Mar 30
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down UK£3.10m from profit in 1H 2021). Profit margin: (down from 60% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 2.4%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Upcoming Dividend • Oct 21
Upcoming dividend of UK£1.00 per share Eligible shareholders must have bought the stock before 28 October 2021. Payment date: 12 November 2021. Trailing yield: 3.9%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (1.0%). Reported Earnings • Oct 19
Full year 2021 earnings released: EPS UK£1.29 (vs UK£1.39 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£10.9m (up 6.0% from FY 2020). Net income: UK£6.73m (down 6.5% from FY 2020). Profit margin: 62% (down from 70% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 11% per year. Reported Earnings • Apr 01
First half 2021 earnings released: EPS UK£0.59 (vs UK£0.67 in 1H 2020) The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£5.16m (up 1.3% from 1H 2020). Net income: UK£3.10m (down 9.6% from 1H 2020). Profit margin: 60% (down from 67% in 1H 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Jan 21
New 90-day high: UK£44.65 The company is up 6.0% from its price of UK£42.10 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. Is New 90 Day High Low • Dec 24
New 90-day high: UK£44.00 The company is up 11% from its price of UK£39.75 on 24 September 2020. The British market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 8.0% over the same period. Reported Earnings • Nov 19
Full year 2020 earnings released: EPS UK£1.39 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£10.3m (up 11% from FY 2019). Net income: UK£7.20m (up 23% from FY 2019). Profit margin: 70% (up from 63% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Nov 19
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Analyst Estimate Surprise Post Earnings • Oct 19
Annual earnings released: Revenue and earnings beat expectations Annual revenue exceeded analyst estimates by 2.1% at UK£10.3m. Earnings per share (EPS) also surpassed analyst estimates by 12% at UK£1.38. Reported Earnings • Oct 19
Full year earnings released - EPS UK£1.39 Over the last 12 months the company has reported total profits of UK£7.20m, up 23% from the prior year. Total revenue was UK£10.3m over the last 12 months, up 11% from the prior year. Profit margins were 70%, which is higher than the 63% margin from last year. The increase in margin was primarily driven by higher revenue. Is New 90 Day High Low • Oct 19
New 90-day high: UK£42.75 The company is up 2.0% from its price of UK£42.00 on 21 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 5.0% over the same period. 
